Fuxiang Co., Ltd. (300497.SZ) announced results for the first half of the year, turning a loss into a profit of 177 million yuan

According to the Zhitong Finance App, Fuxiang Co., Ltd. (300497.SZ) released its 2026 semi-annual report. During the reporting period, the company achieved revenue of 888 million yuan, an increase of 72.59% over the previous year. Achieved net profit of 177 million yuan attributable to shareholders of listed companies. Achieve net profit of 175 million yuan attributable to shareholders of listed companies after deducting non-recurring profit and loss. Basic earnings per share were $0.33. It is proposed to distribute a cash dividend of 0.5 yuan (tax included) for every 10 shares to all shareholders.

During the reporting period, the company's various divisions and functional centers closely followed the established strategy and operated efficiently, and the three major business segments continued to improve in collaboration: the pharmaceutical manufacturing business operated steadily as the basic market; the new energy lithium battery electrolyte additive business clung to the industrial boom cycle and became the core engine of current performance growth; the commercialization process of the biomaneling microbial protein business accelerated, opening up strategic space for medium- to long-term growth.